Recent Updates
Recently added Catalysts
PLRX

Pliant Therapeutics to Participate in BTIG Biotechnology Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D.
Price reaction · baseline $16.5 (2022-08-01 close) · hit after-hours · clean, no other PLRX news in the window
day 0 close · peak
+4.8%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
1.5%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
PLN-101095
Phase 1 · Advanced or Metastatic Solid Tumor

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BTIG Biotechnology Conference 2022.
Panel: Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need
Date: Tuesday, August 9, 2022
Time: 1:00 p.m. ET | 10:00 a.m. PT
The live and replay sessions of the panel discussion will be available to conference registrants via the BTIG Biotechnology Conference 2022 portal.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
Last updated: Aug 2, 2022